Cytokinetics, Incorporated (BIT:1CYTK)

Market Cap	6.64B +37.2%
Revenue (ttm)	74.98M +376.6%
Net Income	-668.55M
EPS	-5.57
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Average Volume	20
Open	51.50
Previous Close	54.00
Day's Range	51.50 - 51.50
52-Week Range	26.60 - 60.50
Beta	n/a
RSI	44.46
Earnings Date	Feb 24, 2026

About Cytokinetics

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in h...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 673
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1CYTK

Financial Performance

In 2025, Cytokinetics's revenue was $88.04 million, an increase of 376.56% compared to the previous year's $18.47 million. Losses were -$784.96 million, 33.2% more than in 2024.

Financial numbers in USD